X4 Pharmaceuticals, Inc. - Common Stock — Bilancio Trimestrale (NASDAQ:XFOR) | MetaTrader

Apri il grafico completo Full chart

Notizie

Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

X4 Pharmaceuticals ottiene l’approvazione UE per farmaco WHIM

Stifel conferma il rating su X4 Pharmaceuticals per progressi negli studi

X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates

ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates

X4 Pharmaceuticals alla Leerink Global Healthcare Conference: Svolta Strategica verso l’Ematologia Rara

X4 Pharmaceuticals at Leerink Global Healthcare Conference: Strategic Shift to Rare Hematology

Guggenheim initiates X4 Pharmaceuticals stock with buy rating

X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval